We measured antibody (anti-HCV) to hepatitis C virus, which causes non-A, non-B hepatitis,
by radioimmunoassay in prospectively followed transfusion recipients and their donors. Of …

Hepatitis C has emerged in recent years as the most common basis for liver disease in the
United States, having infected an estimated 3.9 million people in this country and an …

The beginning of the modern era of blood transfusion coincided with World War II and the
resultant need for massive blood replacement. Soon thereafter, the hazards of transfusion, …

A specific assay has been developed for a blood-borne non-A, non-B hepatitis (NANBH)
virus in which a polypeptide synthesized in recombinant yeast clones of the hepatitis C virus (…

Among 248 asymptomatic blood donors positive for antibody to hepatitis C virus (anti‐HCV)
enrolled in a long‐term prospective study, 86% had chronic HCV infection and 14% …

Bridging the gap between basic scientific advances and the understanding of liver disease—the
extensively revised new edition of the premier text in the field. The latest edition of The …

'Department of Medical Microbiology, Ilniversity of Edinburgh Medical School, Edinburgh
EH8 9AG, UK'Clinica Medica 2. lstituto di Medicina Clinica, Universita di Padova, 35123 …

Patients who receive large numbers of transfusions for anemia and other causes may
develop precipitins in their blood. These precipitins may react in agar gel double diffusion …

Hepatitis C virus (HCV) is the most important etiologic agent of non-A, non-B hepatitis and is
a major cause of chronic liver disease and hepatocellular carcinoma. Development of an …

To clarify the relationship between hepatitis C virus infection and the development of
hepatocellular carcinoma as sequelae of non‐A, non‐B posttransfusion hepatitis, 231 patients with …